Our Focus
The West Virginia Chapter of the National Bleeding Disorders Foundation, WVNBDF, provides education, support, awareness, and advocacy for the bleeding disorder community.
We are the leading resource for West Virginians affected by bleeding disorders. You can count on us to ensure your voice is heard. It’s with your help that we can make a difference. Learn more and get involved.
Our Mission ... Into Action
-
We provide mission-focused experiences through education, support, community connections, and fun for those affected by bleeding disorders.
-
We provide year-round events and fundraisers to spread awareness, educate, and generate crucial resources in support of our mission. Hope to see you at our next event!
-
AdvocacyWe fight to protect access to quality healthcare and treatments we need to live healthy lives, but we can't do it without your voice. Discover how you and your family can make a big difference by joining our advocacy efforts.
News Articles
Roche (and Roche group member Chugai) recently presented data from a phase I/II clinical study of their investigational bispecific antibody therapy NXT007, in people with hemophilia A who do not have factor VIII inhibitors. NXT007 is being positioned as a next-generation subcutaneous prophylactic treatment that builds on the technology used to develop emicizumab (Hemlibra®).
The National Bleeding Disorders Foundation (NBDF) is delighted to announce a new accredited education opportunity for health care providers focused on personalized care for individuals with von Willebrand disease (VWD).
“Restoring Control in von Willebrand Disease: Collaborative Approaches for Delivering the Right Treatment for the Right Patient at the Right Time,” is an enduring activity planned and implemented by the PeerView Institute (PVI) for Medical Education and NBDF.
The U.S. Food and Drug Administration (FDA) has approved the ConcizuTrace™ ELISA Companion Diagnostic (CDx) test, which helps to determine the amount of concizumab-mtci that is circulating in an individual who has taken the product.
Advertisement
Click to learn more.
